Basics Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. IPO Date: April 14, 2004 Sector: Healthcare Industry: Pharma Market Cap: $6.64B Activated in VL: True Average Daily Range Avg Daily Range: $0.26 | 2.80% Avg Daily Range (30 D): $3.31 | 4.16% Avg Daily Range (90 D): $2.12 | 3.06% Institutional Daily Volume Avg Daily Volume: .47M Avg Daily Volume (30 D): 1.74M Avg Daily Volume (90 D): 1.1M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 52 Avg Trade Size (Sh.) (90 D): 49 Institutional Trades Total Inst.Trades: 4,054 Avg Inst. Trade: $2.44M Avg Inst. Trade (30 D): $5.16M Avg Inst. Trade (90 D): $4.88M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.29M Avg Closing Trade (30 D): $15.89M Avg Closing Trade (90 D): $12.22M Avg Closing Volume: 137.75K         News Dec 11, 2024 @ 6:00 PM Alcohol Use Disorder Market Set for Remarkable Gro... Source: Delveinsight Sep 19, 2024 @ 7:36 PM Corcept Moves 6.5% Higher: Will This Strength Last... Source: Zacks Sep 3, 2024 @ 8:29 PM Corcept Shares Rise More Than 45% in Six Months: H... Source: Zacks Aug 6, 2024 @ 10:20 AM Should You Invest in the First Trust NYSE Arca Bio... Source: Zacks Investment Research Jun 26, 2024 @ 3:13 PM Corcept (CORT) Shares Rise 20% in Three Months: He... Source: Zacks Equity Research Financials   TTM Q4 2024 FY 2024 Basic EPS $1.35 $.29 $1.35 Diluted EPS $1.23 $.25 $1.23 Revenue $ 675.04M $ 181.89M $ 675.04M Gross Profit $ 664.16M $ 178.93M $ 664.16M Net Income / Loss $ 141.21M $ 30.75M $ 141.21M Operating Income / Loss $ 136.95M $ 25.26M $ 136.95M Cost of Revenue $ 10.88M $ 2.96M $ 10.88M Net Cash Flow $ -7.89M $ -9.62M $ -7.89M PE Ratio 59.01